Acute coronary syndrome
356 results
101 - 200
After 1 month of DAPT after PCI for acute coronary syndromes, ticagrelor monotherapy results in similar outcomes with less bleeding than ticagrelor plus aspirin- Early CT angiography for suspected acute coronary syndrome reduces further ischemic testing; no effect on long-term clinical outcomes
- For treatment of acute coronary syndrome, prasugrel is better than ticagrelor at preventing recurrent MIs at 1 year
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes: Cochrane systematic review- PSK9 inhibitor alirocumab reduces nonfatal MI in patients after acute coronary syndrome, but at high cost (ODYSSEY OUTCOMES)
- Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome
- Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes: Cochrane systematic review
Chronic coronary syndrome (coronary heart disease) - Dabigatran associated with increased risk of coronary events
- Additional testing of limited benefit in patients with new-onset chest pain
- Coronary CT angiogram allows for safe discharge of low-risk patients with chest pain
- Less bleeding with fondaparinux vs enoxaparin for ACS with PCI
- FDA: Clopidogrel/aspirin does not decrease overall mortality
- Faster discharge but more downstream testing with use of CCTA in ED
- HET score: atypical chest pain + normal ECG + normal troponin = no acute coronary event
- Intensive versus moderate statin therapy
- Signs and symptoms not helpful in diagnosis of AMI/ACS
- Bivalirudin = abciximab + heparin for non-STEMI
- For atrial fibrillation with ACS or PCI, apixaban plus clopidogrel (without aspirin) is preferred (AUGUSTUS)
- Ranolazine (Ranexa) not effective for ACS
- Genotype-guided selection of oral P2Y12 inhibitor therapy no better than standard therapy after PCI for ACS or stable CAD
- Intensive lipid lowering adds additional benefit
- Invasive strategy best only for men and high-risk women with unstable angina/non-ST elevation MI
- Clopidogrel + ASA no better than ASA alone for high-risk patients
- Ruling out acute myocardial infarction based on patient characteristics
- Pain severity does not predict outcomes with AMI
- Intensive lipid lowering reduces mortality following ACS
- Improved outcomes with early invasive strategy for ACS? Maybe, maybe not.
- ED chest pain protocol is safe and efficient
- ACC/AHA guidelines on dual antiplatelet therapy
- Flu vaccine reduces risk of adverse CV events in high-risk patients
- Low-dose rivaroxaban improves outcomes in patients with ACS (ATLAS)
- Two-hour protocol identifies patients at low risk of ACS
- Mortality rate in patients with recent ACS and endoscopy is similar to that in patients with ACS and no endoscopy
- Apixaban increases bleeding with no benefit in high-risk patients with ACS
- No reduction in postdischarge medication errors after pharmacist-led intervention
- Concomitant use of clopidogrel and a PPI may increase risk of adverse CHD outcomes
- Early invasive therapy better for non-ST ACS
- CCTA reduces need for hospitalization in low to moderate risk patients in ED
- Better medication adherence with intervention; clinical outcomes unchanged
- Interpretation of adult ECG
- Antithrombotic agents in primary health care
- Routine stress testing after negative biomarker testing seldom helpful
- Early initiation of statins following ACS does not improve outcomes
- ACS risk similar with normal ECG performed during presence or absence of chest pain
- Evacetrapib increases HDL but does nothing for patient-oriented outcomes
- In ACS, 5 yrs of invasive tx decreases MI but not all cause mortality (FRISC-II)
- In low-risk patients with ACS, noninvasive testing adds little to clinical evaluation
- Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events
- Low HS-troponin I accurate in identifying patients at low risk of cardiac events
- Dyspepsia
- Exercise stress test
- ACC/AHA guideline for the management of patients with chronic coronary disease
- Platelet-function testing doesn't improve outcomes in elderly patients with stents after ACS
- Early angiography not crucial in low risk NSTEMI patients (TIMACS)
- Adding ezetimibe to moderate-dose statin reduces nonfatal MI only (NNT = 58 for 6 years)
- Intravenous immunoglobulin for the treatment of Kawasaki disease
- Accelerated protocol identifies chest pain patients at low risk for major cardiac events